Recently, the Thailand FDA has brought a revised list of Institutional Review Boards (IRBs)/Ethics Committees (ECs) that it recognizes for acceptance of clinical trial applications. In our previous articles (see Part I and Part II), we’ve discussed the regulatory scenario in Thailand, including We’ve also presented a list of ethics committees that are recognized for application to the […]
Read More →With patients with ovarian cancer as the target trial population, clinical trial feasibility was performed. The clinical trial sites/investigators, who participated in this feasibility came mainly from India, Russia, the Philippines, Vietnam, Thailand, and South Korea. What are the causes of ovarian cancer? The causes of ovarian cancer are unclear but doctors have identified factors that […]
Read More →Worldwide, breast cancer is the most common invasive cancer in women. Along with lung cancer, breast cancer is the most commonly diagnosed cancer, with 2.09 million cases each in 2018, and Breast cancer affects 1 in 7 (14%) of women worldwide. What is breast cancer? Breast cancer is a cancer that develops from breast tissue. […]
Read More →Thailand furnishes a good infrastructure, and a robust and flexible regulatory process to conduct clinical trials. There is a rise in the interest of many pharma companies and research organizations in conducting clinical trials in Thailand. Continuation from Clinical Trial Regulatory & Approval Process In Thailand (Part-1). We often receive queries from pharmaceutical companies and clinical […]
Read More →Among 10 ASEAN countries, Thailand registers the highest number of clinical trials in the region, and the number of BA/BE studies is increasing. The regulatory process and requirements to conduct clinical trials in Thailand are of interest to many pharmaceutical companies. We often receive queries from pharmaceutical companies and clinical research organizations asking about the […]
Read More →